Baricitinib for the treatment of refractory vascular Behçet's disease

• Published in: Clinical immunology (Orlando, Fla.) Vol. 250; p. 109298
• Main Authors: Wang, Zhimian, Wang, Xiaoou, Liu, Weiwei, Wang, Yuhua, Liu, Jinjing, Zhang, Li, Zhang, Shangzhu, Tian, Xinping, Zhao, Yan, Zheng, Wenjie
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2023
• Subjects: Baricitinib; Behcet Syndrome - drug therapy; Behçet's disease; Biologics therapy; Glucocorticoids - therapeutic use; Humans; Immunosuppressive Agents - therapeutic use; Male; Pilot Projects; Refractory; Sulfonamides - therapeutic use; Treatment Outcome; Vascular/cardiac involvement; Refractory; Vascular/cardiac involvement; Behçet's disease; Biologics therapy; Baricitinib

The pilot study aims to evaluate the effectiveness and safety of baricitinib in Behcet's Disease (BD) patients with refractory vascular involvement. We consecutively enrolled vascular/cardiac BD patients who received baricitinib (2 mg/day) along with glucocorticoids (GCs) and immunosuppressants...